UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 5)*

Halozyme Therapeutics, Inc.

(Name of issuer)

Common Stock, par value \$0.001 per share (Title of class of securities)

40637H109 (CUSIP number)

December 31, 2009 (Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8 pages

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 40637H109					
1.	Names of reporting persons. I.R.S. Identification Nos. of above persons (entities only).				
	QVT Financial LP 11-3694008				
2.	Check the appropriate box if a member of a group (see instructions) (a) □ (b) ⊠				
3.	SEC use only				
4.	Citizenship or place of organization				
	Delaware				
		5.	Sole voting power		
Nι	ımber of		0		
	shares	6.	Shared voting power		
	neficially wned by		4,244,844		
	each	7.	Sole dispositive power		
	porting person		0		
	with:	8.			
			4,244,844		
9.					
	4,244,844				
10.	Check if the aggregate amount in Row (9) excludes certain shares (see instructions) \Box				
11.	Percent of class represented by amount in Row (9)				
	4.63%				
12.	Type of reporting person (see instructions)				
	PN				

Page 2 of 8 pages

CUSIP No. 40637H109					
1.	Names of reporting persons. I.R.S. Identification Nos. of above persons (entities only).				
	QVT Financial GP LLC 11-3694007				
2.	Check the appropriate box if a member of a group (see instructions) (a) □ (b) ⊠				
3.	SEC use only				
4.	. Citizenship or place of organization				
	Delaware				
		5.	Sole voting power		
Number of			0		
	shares	6.	Shared voting power		
	neficially vned by		4,244,844		
	each	7.	Sole dispositive power		
	porting person		0		
	with:	8.			
			4,244,844		
9.					
	4,244,844				
10.	Check if the aggregate amount in Row (9) excludes certain shares (see instructions)				
11.	Percent of class represented by amount in Row (9)				
	4.63%				
12.	Type of reporting person (see instructions)				
	00				

Page 3 of 8 pages

CUSIP No. 40637H109					
1.	Names of reporting persons. I.R.S. Identification Nos. of above persons (entities only).				
	QVT Fund LP 98-0415217				
2.	Check the appropriate box if a member of a group (see instructions) (a) □ (b) ⊠				
3.	SEC use only				
4.	. Citizenship or place of organization				
	Cayman Islands				
			Sole voting power		
Νι	imber of		0		
shares beneficially		6.	Shared voting power		
	vned by		3,938,806		
	each	7.	Sole dispositive power		
re	porting				
	person		0		
	with:	8.	Shared dispositive power		
			3,938,806		
9.					
	3,938,806				
10.	Check if the aggregate amount in Row (9) excludes certain shares (see instructions)				
11.	Percent of class represented by amount in Row (9)				
	4.3%				
12.	Type of reporting person (see instructions)				
	PN				

Page 4 of 8 pages

CUSIP No. 40637H109					
1.	Names of reporting persons. I.R.S. Identification Nos. of above persons (entities only).				
	QVT Associates GP LLC 01-0798253				
2.	Check the appropriate box if a member of a group (see instructions) (a) □ (b) ⊠				
3.	SEC use only				
4.	. Citizenship or place of organization				
	Delaware				
		5.	Sole voting power		
Number of			0		
	shares	6.	Shared voting power		
	neficially vned by		4,244,844		
0,	each	7.	Sole dispositive power		
	porting person		0		
	with:	8.			
		٥.			
9.	9. Aggregate amount beneficially owned by each reporting person				
10.	4,244,844 Check if the aggregate amount in Row (9) excludes certain shares (see instructions) □				
11.	Percent of class represented by amount in Row (9)				
	4.63%				
12.	Type of reporting person (see instructions)				
	00				

Page 5 of 8 pages

Item 1	(a).	Name of Issuer
		Halozyme Therapeutics, Inc. (the "Issuer")
Item 1	(b).	Address of Issuer's Principal Executive Offices
		The address of the Issuer's principal executive offices is: 11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121
Item 2	(a).	Name of Person Filing
Item 2	(b).	Address of Principal Business Office or, if none, Residence
Item 2	(c).	Citizenship
		QVT Financial LP 1177 Avenue of the Americas, 9th Floor New York, New York 10036 Delaware Limited Partnership
		QVT Financial GP LLC 1177 Avenue of the Americas, 9th Floor New York, New York 10036 Delaware Limited Liability Company
		QVT Fund LP Walkers SPV, Walkers House Mary Street George Town, Grand Cayman, KY1 9001 Cayman Islands Cayman Islands Limited Partnership
		QVT Associates GP LLC 1177 Avenue of the Americas, 9th Floor New York, New York 10036 Delaware Limited Liability Company
Item 2	(d).	Title of Class of Securities
		The title of the securities is common stock, par value \$0.001 per share (the "Common Stock").
Item 2	(e).	CUSIP Number
		The CUSIP number of the Common Stock is 40637H109.
Item 3.	If this s	statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	(a)	☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
	(b)	\square Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
	(f)	☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
	(g)	☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
	(h)	☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
	(k)	☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(I), please specify the type of institution:

Item 4. Ownership.

(a) Amount beneficially owned:

QVT Financial LP ("QVT Financial") is the investment manager for QVT Fund LP (the "Fund"), which beneficially owns 3,938,806 shares of Common Stock, and for Quintessence Fund L.P. ("Quintessence"), which beneficially owns 306,038 shares of Common Stock. QVT Financial has the power to direct the vote and disposition of the Common Stock held by the Fund and Quintessence. Accordingly, QVT Financial may be deemed to be the beneficial owner of an aggregate amount of 4,244,844 shares of Common Stock, consisting of the shares owned by the Fund and Quintessence.

QVT Financial GP LLC, as General Partner of QVT Financial, may be deemed to beneficially own the same number of shares of Common Stock reported by QVT Financial. QVT Associates GP LLC, as General Partner of the Fund and Quintessence, may be deemed to beneficially own the aggregate number of shares of Common Stock owned by the Fund and Quintessence, and accordingly, QVT Associates GP LLC may be deemed to be the beneficial owner of an aggregate amount of 4,244,844 shares of Common Stock.

As of December 31, 2009, the Fund beneficially owned 4,167,259 shares of Common Stock and Quintessence beneficially owned 352,585 shares of Common Stock. Accordingly, as of December 31, 2009, QVT Financial, QVT Financial GP LLC and QVT Associates GP LLC each may have been deemed to be the beneficial owner of 4,519,844 shares of Common Stock.

Each of QVT Financial and QVT Financial GP LLC disclaim beneficial ownership of the shares of Common Stock owned by the Fund and Quintessence. QVT Associates GP LLC disclaims beneficial ownership of all shares of Common Stock owned by the Fund and Quintessence, except to the extent of its pecuniary interest therein.

The percentage disclosed in Item 11 of the Cover Pages for each reporting person is calculated based upon 91,647,241 shares of Common Stock outstanding, which is the total number of shares of Common Stock issued and outstanding as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 and filed with the Securities and Exchange Commission on November 6, 2009.

(b) Percent of class:

See Item 11 of the Cover Pages to this Schedule 13G.

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote

0

(ii) Shared power to vote or to direct the vote

See item (a) above.

(iii) Sole power to dispose or to direct the disposition of

0

(iv) Shared power to dispose or to direct the disposition of

See item (a) above.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \boxtimes .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of

the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 7 of 8 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2010

QVT FINANCIAL LP QVT FUND LP By QVT Financial GP LLC, By QVT Associates GP LLC, its General Partner its General Partner By: /s/ O REN E ISNER By: /s/ O REN E ISNER Name: Oren Eisner Name: Oren Eisner **Authorized Signatory Authorized Signatory** Title: Title: **QVT FINANCIAL GP LLC** QVT ASSOCIATES GP LLC By: O REN E ISNER By: O REN E ISNER Oren Eisner Name: Oren Eisner Name: **Authorized Signatory Authorized Signatory** Title: Title:

Page 8 of 8 pages